Found: 64
Select item for more details and to access through your institution.
Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
- Published in:
- International Journal of Hematology, 2014, v. 99, n. 4, p. 441, doi. 10.1007/s12185-014-1539-5
- By:
- Publication type:
- Article
Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis.
- Published in:
- 2013
- By:
- Publication type:
- Report
Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation.
- Published in:
- 2013
- By:
- Publication type:
- Report
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
- Published in:
- International Journal of Hematology, 2012, v. 95, n. 5, p. 516, doi. 10.1007/s12185-012-1035-8
- By:
- Publication type:
- Article
Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
- Published in:
- 2010
- By:
- Publication type:
- research
The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 6, p. 2919, doi. 10.3390/ijms23062919
- By:
- Publication type:
- Article
Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/ refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
- Published in:
- Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1476
- By:
- Publication type:
- Article
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-32426-6
- By:
- Publication type:
- Article
Management of Acquired Factor X Deficiency Caused by In Vitro Non-neutralizing Anti-factor X Autoantibodies with Pre-emptive Corticosteroid Therapy.
- Published in:
- Internal Medicine, 2023, v. 62, n. 16, p. 2401, doi. 10.2169/internalmedicine.0849-22
- By:
- Publication type:
- Article
Gastric Myeloid Sarcoma Mimicking a Scirrhous Gastric Cancer.
- Published in:
- Internal Medicine, 2022, v. 61, n. 8, p. 1231, doi. 10.2169/internalmedicine.7986-21
- By:
- Publication type:
- Article
Tumour‐derived exosomes promote the induction of monocytic myeloid‐derived suppressor cells from peripheral blood mononuclear cells by delivering miR‐106a‐5p and miR‐146a‐5p in multiple myeloma.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 3, p. 426, doi. 10.1111/bjh.19049
- By:
- Publication type:
- Article
Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 2, p. 256, doi. 10.1111/bjh.18831
- By:
- Publication type:
- Article
Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma.
- Published in:
- British Journal of Haematology, 2020, v. 191, n. 5, p. 784, doi. 10.1111/bjh.16881
- By:
- Publication type:
- Article
Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/ RPS6 KA3 signalling axis in multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 4, p. 534, doi. 10.1111/bjh.14707
- By:
- Publication type:
- Article
Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 2, p. 210, doi. 10.1007/s10637-018-0623-8
- By:
- Publication type:
- Article
Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
- Published in:
- Journal of Clinical Apheresis, 2013, v. 28, n. 5, p. 368, doi. 10.1002/jca.21283
- By:
- Publication type:
- Article
Mantle cell lymphoma with EBV‐positive Hodgkin and Reed–Sternberg‐like cells in a patient after autologous PBSCT: Phenotypically distinct but genetically related tumors.
- Published in:
- Pathology International, 2021, v. 71, n. 1, p. 96, doi. 10.1111/pin.13038
- By:
- Publication type:
- Article
Neurolymphomatosis of cranial nerves as the responsible lesions for the vocal cord paralysis and facial nerve palsy in a patient with diffuse large B-cell lymphoma.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 2, p. 481, doi. 10.1007/s00277-022-05038-9
- By:
- Publication type:
- Article
Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Primary intraocular natural killer-cell lymphoma successfully treated using a multidisciplinary strategy.
- Published in:
- 2019
- By:
- Publication type:
- Case Study
Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
- Published in:
- 2015
- By:
- Publication type:
- Letter
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 7, p. 1, doi. 10.1007/s00262-024-03711-8
- By:
- Publication type:
- Article
Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 2206, doi. 10.3390/cancers12082206
- By:
- Publication type:
- Article
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 4, p. 555, doi. 10.1111/ejh.13586
- By:
- Publication type:
- Article
Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 3, p. 3134, doi. 10.1002/cam4.5237
- By:
- Publication type:
- Article
Serine‐227 in the N‐terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 14, p. 5185, doi. 10.1002/cam4.3136
- By:
- Publication type:
- Article
Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 3, p. 655, doi. 10.1002/cam4.1342
- By:
- Publication type:
- Article
Monocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomide.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221142487
- By:
- Publication type:
- Article
Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221104584
- By:
- Publication type:
- Article
Double-hit Lymphomas Constitute a Highly Aggressive Subgroup in Diffuse Large B-cell Lymphomas in the Era of Rituximab.
- Published in:
- Japanese Journal of Clinical Oncology, 2012, v. 42, n. 11, p. 1035, doi. 10.1093/jjco/hys148
- By:
- Publication type:
- Article
Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms.
- Published in:
- Infection & Drug Resistance, 2023, v. 16, p. 509, doi. 10.2147/IDR.S396271
- By:
- Publication type:
- Article
Clinical Implication of the Effect of the Production of Neutralizing Antibodies Against SARS-Cov-2 for Chronic Immune Thrombocytopenia Flare-Up Associated with COVID-19 Infection: A Case Report and the Review of Literature.
- Published in:
- Infection & Drug Resistance, 2022, v. 15, p. 2723, doi. 10.2147/IDR.S360238
- By:
- Publication type:
- Article
Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome.
- Published in:
- Case Reports in Oncology, 2014, v. 7, n. 1, p. 188, doi. 10.1159/000360905
- By:
- Publication type:
- Article
Chronic Invasive Fungal Rhinosinusitis with Atypical Clinical Presentation in an Immunocompromised Patient.
- Published in:
- Infection & Drug Resistance, 2020, v. 13, p. 3225, doi. 10.2147/IDR.S273317
- By:
- Publication type:
- Article
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.
- Published in:
- Infection & Drug Resistance, 2020, v. 13, p. 1017, doi. 10.2147/IDR.S249030
- By:
- Publication type:
- Article
Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab.
- Published in:
- Infection & Drug Resistance, 2018, v. 11, p. 701, doi. 10.2147/IDR.S163686
- By:
- Publication type:
- Article
Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma.
- Published in:
- Journal of Clinical & Experimental Hematopathology, 2021, v. 61, n. 2, p. 71, doi. 10.3960/jslrt.20033
- By:
- Publication type:
- Article
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
- Published in:
- International Journal of Hematology, 2024, v. 119, n. 6, p. 697, doi. 10.1007/s12185-024-03750-y
- By:
- Publication type:
- Article
Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.
- Published in:
- International Journal of Hematology, 2024, v. 119, n. 1, p. 50, doi. 10.1007/s12185-023-03680-1
- By:
- Publication type:
- Article
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum.
- Published in:
- International Journal of Hematology, 2023, v. 118, n. 5, p. 609, doi. 10.1007/s12185-023-03653-4
- By:
- Publication type:
- Article
Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.
- Published in:
- International Journal of Hematology, 2023, v. 118, n. 3, p. 323, doi. 10.1007/s12185-023-03627-6
- By:
- Publication type:
- Article
EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.
- Published in:
- International Journal of Hematology, 2021, v. 113, n. 3, p. 381, doi. 10.1007/s12185-020-03027-0
- By:
- Publication type:
- Article
Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry.
- Published in:
- International Journal of Hematology, 2020, v. 112, n. 4, p. 435, doi. 10.1007/s12185-020-02996-6
- By:
- Publication type:
- Article
Toward further simplification of elotuzumab therapy by subcutaneous administration.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
- Published in:
- 2019
- By:
- Publication type:
- journal article